Christopher van Dyck, MD
Cards
About
Titles
Elizabeth Mears and House Jameson Professor of Psychiatry and of Neurology and Neuroscience
Director, Alzheimer's Disease Research Unit; Director, Yale Alzheimer's Disease Research Center; Director, Division of Aging and Geriatric PsychiatryBiography
Christopher H. van Dyck, MD, is Professor of Psychiatry, Neurology, and Neuroscience; Director of the Alzheimer's Disease Research Unit; Director, Yale Alzheimer's Disease Research Center; Director, Division of Aging and Geriatric Psychiatry.
His research focuses on neuroimaging and therapeutic studies of Alzheimer’s disease (AD) and brain aging. His current imaging research utilizes positron emission tomography (PET) to study the beta-amyloid (Aβ) and tau proteins, as well as the synaptic targets SV2A and mGluR5. He and his team are examining the full spectrum of AD, including AD-dementia, the prodromal condition of amnestic Mild Cognitive Impairment (aMCI), and preclinical AD—in individuals at high familial and genetic risk.
He also has extensive experience in the conduct and leadership of therapeutic trials in AD. Since 1991 he has led or participated in approximately 90 clinical trials for AD, including the prodromal or preclinical stages. He currently serves on the Steering and Executive Committees and Co-Chairs the Protocol Evaluation Committee of the Alzheimer’s Clinical Trials Consortium (ACTC). His research accomplishments have been recognized by receipt of the 1996 Junior Investigator Award of the American Association of Geriatric Psychiatry, the 2005 Compassion and Cure Award of the Alzheimer’s Association, and the 2017 Leader in Advancing Research Award of the Alzheimer’s Association.
Appointments
Psychiatry
ProfessorPrimaryNeuroscience
ProfessorSecondaryNeurology
ProfessorSecondary
Other Departments & Organizations
- Alzheimer's Disease Research Center (ADRC)
- Alzheimer's Disease Research Unit
- Division of Aging & Geriatric Psychiatry
- Dorothy Adler Geriatric Assessment Center
- Interdepartmental Neuroscience Program
- Neural Disorders
- Neurology
- Neuroscience
- Neuroscience Research Training Program (NRTP)
- Neuroscience Track
- Psychiatry
- Wu Tsai Institute
- Yale Combined Program in the Biological and Biomedical Sciences (BBS)
- Yale Medicine
- Yale Ventures
Education & Training
- MD
- Northwestern University (1984)
- BA
- Yale University (1978)
- Resident
- Yale-New Haven Hospital
- Fellow
- Yale University School of Medicine
Research
Academic Achievements and Community Involvement
Clinical Care
Overview
Clinical Specialties
Fact Sheets
Alzheimer's Disease
Learn More on Yale MedicineDementia
Learn More on Yale MedicineObsessive-Compulsive Disorder in Children
Learn More on Yale MedicineOpioid Use Disorder
Learn More on Yale Medicine
Board Certifications
Geriatric Psychiatry
- Certification Organization
- AB of Psychiatry & Neurology
- Latest Certification Date
- 2013
- Original Certification Date
- 1994
Psychiatry
- Certification Organization
- AB of Psychiatry & Neurology
- Original Certification Date
- 1991
Yale Medicine News
Links & Media
Media
Synaptic density (DVR) in Alzheimer's Disease and Cognitively Normal groups determined by [11C]UCB-J PET.
Coronal sections of average parametric images of DVR for (A) 19 Cognitively Normal participants and (B) 34 Alzheimer's Disease participants. Average images are created after co-registration to a common template. The average parametric PET scans are displayed in pseudocolor representing [11C]UCB-J binding to SV2A (DVR) and overlaid on the Montreal Neurological Institute (MNI) template T1 MRI. Lower DVR in Alzheimer's Disease compared to Cognitively Normal participants was apparent in the medial temporal lobe and throughout the cortex and subcortex.
News
- March 20, 2023
Jain Receives AHA Career Development Award
- January 19, 2023Source: Yale Medicine
Lecanemab, the New Alzheimer’s Treatment: 3 Things To Know
- January 09, 2023
Alzheimer's Drug Validated in Yale-led Trial Gets FDA Accelerated Approval
- January 04, 2023Source: YaleNews
Drug Slows Clinical Decline of Patients With Early-stage Alzheimer’s in Yale-led Study